PSNL
Personalis, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Personalis, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
No thesis.
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; of Personalis, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Labcorp Holdings Inc., Veracyte, Inc. and 3 more; of Personalis, Inc.'s 6 closest co-movers, none share that code.
0.00%
vs ±10.9% implied · ×0.00
shaded = implied · ▲▼ = realized
Personalis, Inc.
15.83
−0.10 · −0.61%
post 15.83 +0.01%
—
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Merck | $188.2M | 16.31% | 0.00% |
| ARK | $110.8M | 9.61% | +4.12% |
| BlackRockindex-like | $94.9M | 8.22% | +31.40% |
| Lightspeed | $81.8M | 7.09% | −25.23% |
| Ameriprise Financial | $81.6M | 7.07% | −19.84% |
| Manager | Value | % base | |
|---|---|---|---|
| Merck | $188.2M | 16.31% | 0.00% |
| ARK | $110.8M | 9.61% | +4.12% |
| BlackRockindex-like | $94.9M | 8.22% | +31.40% |
| Lightspeed | $81.8M | 7.09% | −25.23% |
| Ameriprise Financial | $81.6M | 7.07% | −19.84% |
Bull2
Bear1
Expected move
Inputs8Q avg ±9.9%·×1.03·fair
straddle ±11.8%
spot 15.82exp Nov 20ATM strike 15ATM straddle 2.20IV 71%